Research Signal – Source date 2026-07-28
Physical recovery can make a rehabilitation ward look like a place where the body is the main subject. Yet a person rebuilding strength after cardiac or pulmonary illness, or regaining function after an orthopedic condition, may also be dealing with difficulties in memory, language, or attention. When clinical attention is focused mainly on physical recovery, those problems can remain unrecognized.
The COGinREHAB study is designed to investigate how often cognitive impairment appears in this setting and how often it was not previously documented. The prospective study is being conducted at three Fondazione Don Carlo Gnocchi rehabilitation centers in Florence and Milan. It plans to enroll 384 adults aged 45 or older who are hospitalized for non-neurological conditions in cardiac, pulmonary, or orthopedic intensive rehabilitation units or intermediate care units.
The supplied ClinicalTrials.gov record describes COGinREHAB as recruiting and records an actual study start on January 20, 2026. Those details describe the study’s registry status and design, not results from the planned assessments.
Why cognition belongs in a rehabilitation ward
The study focuses on a practical problem. A patient may enter rehabilitation because of a heart, lung, or orthopedic condition, while memory and thinking are not the reason for admission. The rehabilitation team still needs to understand how the patient processes instructions, remembers information, manages attention, and participates in a demanding schedule. The protocol therefore places cognitive assessment alongside the medical and functional information already gathered during rehabilitation.
The question is not whether every patient has a neurological disorder. The study is looking for a broader range of cognitive difficulty, including patterns that may fit mild cognitive impairment or other cognitive dysfunction. Its diagnostic purpose is to estimate how common these problems are in the selected rehabilitation population and to describe the people in whom they are found.
Screening is the first branch in the pathway
All participants begin with a screening visit within 10 days of admission, taking about 60 minutes. The team reviews medical records for any previous documentation of cognitive status, collects demographic and clinical information, and administers the Montreal Cognitive Assessment alongside measures of mood, lifestyle, cognitive reserve, motor reserve, and current physical activity.
The screening score is a routing tool, not the study’s final classification. Participants whose MoCA Equivalent Score is 0 or 1 overall, or in at least one cognitive domain including the Memory Index Score, proceed to a more extensive neuropsychological assessment. The protocol also specifies a separate severe-score branch: participants with a corrected MoCA total score below 15.485, more than two standard deviations below normative values, are excluded from further baseline assessment because the result is treated as indicative of severe cognitive impairment.
That sequence matters because a positive screen and a confirmed cognitive profile are different things. The broader assessment tests memory with tasks such as verbal learning and visual recall, language with naming and verbal fluency, and attention or executive function with measures including trail-making and Stroop tasks. Rather than relying on one low score, the study confirms impairment when performance is sufficiently low on at least two tests within one domain, or on at least one test in each of three domains.
The threshold is also tied to adjusted norms. An Equivalent Score of 1 or below corresponds to performance below the 20th percentile of the demographically adjusted normative distribution. In plain terms, the study is designed to distinguish an initial indication that more assessment is needed from a pattern of low performance across formal tests.
Deeper testing asks a different question
Once cognitive impairment is confirmed, the study moves beyond classification. It asks whether the cognitive profile is related to biological, genetic, imaging, and physiological measurements.
Blood samples are used to measure GFAP, neurofilament light chain, and phosphorylated tau-217, all described as plasma biomarkers of neurodegeneration in the registry record. Participants in this confirmed-impairment group also undergo APOE genotyping, including the number of APOE ε4 copies, and a non-contrast brain CT scan. The purpose is to examine how these measurements relate to cognitive performance and later change, rather than to present any marker as a stand-alone answer.
Some measurements are limited to a subset of participants. Those assessments include resting-state EEG, auditory P300 event-related potentials, actigraphy for sleep-wake monitoring, and overnight polysomnography. The subset design means that the most detailed physiological and sleep profile will not necessarily be available for every participant with confirmed impairment. It also makes the resulting comparisons more specific: the study can explore associations among selected measures, but the registry description does not establish that any sleep pattern, genetic variation, or blood-marker level causes cognitive impairment.
The twelve-month visit is about change
The study does not stop at the admission profile. Participants with confirmed cognitive impairment at baseline are invited to return 12 months later. The follow-up includes a new MoCA, the same neuropsychological battery where possible using alternative forms, updated medication and illness information, repeat measurements of GFAP, neurofilament light chain, and phosphorylated tau-217, and repeat resting-state EEG.
This creates a within-person comparison. Researchers can ask whether an individual’s cognitive scores and selected biological or EEG measures changed together over the year. The protocol describes these as longitudinal associations to be analyzed, not as an assumption that one measurement predicts or causes another. APOE genotyping and brain CT are part of the baseline work-up, while the recorded follow-up pathway specifically emphasizes repeat cognitive, blood, and resting-state EEG measures.
What future prevalence estimates would mean
A future prevalence estimate from COGinREHAB would describe the patients who entered these three Italian centers and passed through this study’s assessment pathway. It would not automatically represent all older adults, every rehabilitation ward, or people recovering from other conditions.
The estimate will also depend on the study’s branching structure. Everyone receives screening, but only some participants move to the full neuropsychological battery, and the protocol sends those with severe screening scores out of further baseline assessment. The supplied procedures do not settle how participants in that severe-score branch will enter every eventual prevalence calculation. That detail is important when interpreting any final percentage.
The current registry record gives an estimated primary completion in November 2027 and estimated overall completion in December 2028. Those dates are planning information. The supplied material contains the study’s objectives, procedures, and planned statistical comparisons, but no participant-level prevalence, no count of previously unrecognized cases, and no evidence that the target enrollment of 384 has been achieved.
The study’s single-group diagnostic design can describe the burden and profile of cognitive impairment in this selected setting. It cannot by itself show that screening improves physical recovery, prevents institutionalization, or prevents dementia. Nor would a relationship between cognition and a biomarker, sleep measure, EEG feature, or APOE variation establish a causal pathway.
How cognitive assessment could shape rehabilitation care
The potential practical benefit is concrete but still conditional. Recognizing memory and thinking difficulties could help rehabilitation teams adapt explanations, rehabilitation instructions, and follow-up support to a patient’s needs. That possibility depends first on useful detection in this setting and then on evidence that acting on the findings benefits patients.
COGinREHAB is therefore testing an assessment pathway, not demonstrating a finished care model. Its value will depend on what the staged screening, deeper testing, and follow-up ultimately reveal, and on whether those findings can be translated into support that makes rehabilitation more understandable and workable for the people receiving it.
Key Sources
- Primary source: Prevalence of Mild Cognitive Impairment and Dementia in Patients Admitted to Non-neurological Rehabilitation Wards
Government or Regulator · Clinical Trial · 2026-07-28
Keep exploring